2-N-[(2S,3S)-3-hydroxy-4-oxo-1-phenyl-4-[3-(2H-tetrazol-5-yl)anilino]butan-2-yl]-4-oxo-6-N-[(1R)-1-phenylethyl]pyran-2,6-dicarboxamide | 1022893-01-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-N-[(2S,3S)-3-hydroxy-4-oxo-1-phenyl-4-[3-(2H-tetrazol-5-yl)anilino]butan-2-yl]-4-oxo-6-N-[(1R)-1-phenylethyl]pyran-2,6-dicarboxamide
• CAS: 1022893-01-1
• 化学式: C₃₂H₂₉N₇O₆
• 分子量: 607.626
• InChiKey: RMAQSUPUFBVKQM-ATVOGRQSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  45
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  188
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  6-[[(2S,3S)-3-hydroxy-4-oxo-1-phenyl-4-[3-(2H-tetrazol-5-yl)anilino]butan-2-yl]carbamoyl]-4-oxopyran-2-carboxylic acid 、 R(+)-alpha-甲基苄胺 以2%的产率得到2-N-[(2S,3S)-3-hydroxy-4-oxo-1-phenyl-4-[3-(2H-tetrazol-5-yl)anilino]butan-2-yl]-4-oxo-6-N-[(1R)-1-phenylethyl]pyran-2,6-dicarboxamide
  参考文献：
  名称：

  NOVEL COMPOUND HAVING SECRETASE INHIBITORY ACTIVITY

  摘要：

  下面的公式（1）表示的一种新化合物具有β-分泌酶抑制活性，其药用可接受的盐或其前药。其中Ar是取代或未取代的5至6个成员单环芳香基团；R1、R2和R3是氢原子，取代或未取代的烷基或类似物，或R2和R3可以分别与相邻的氮原子和碳原子结合形成3至6个成员环；R4是C1-6烷基，C1-6烷基被苯基，苯硫基或杂环取代，或类似物取代；A由以下公式表示：其中X和Y是氧原子，NH或硫原子，Z是氢原子，可被取代的羟基，氨基，硫醇基等；B是羟基，取代或未取代的氨基，取代或未取代的脂肪或芳香氨基，或类似物。

  公开号：

  EP2168947A1

文献信息

• Novel non-peptidic and small-sized BACE1 inhibitors
  作者：Yoshio Hamada、Hiroko Ohta、Naoko Miyamoto、Ryoji Yamaguchi、Abdellah Yamani、Koushi Hidaka、Tooru Kimura、Kazuki Saito、Yoshio Hayashi、Shoichi Ishiura、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2008.01.056

  日期：2008.3

  Recently, we reported substrate-based beta-secretase (BACE1) inhibitors with a hydroxymethylcarbonyl (HMC) isostere as a substrate transition-state mimic. These inhibitors showed potent BACE1 inhibitory activities (similar to 1.2 nM IC50). In order to improve in vivo enzymatic stability and permeability across the blood-brain barrier, these penta-peptidic inhibitors would need to be further optimized. On the other hand, non-peptidic inhibitors possessing isophthalic residue at the P-2 position were reported from other research groups. We selected isophthalic-type aromatic residues at the P-2 position and an HMC isostere at the P-1 position as lead compounds. On the basis of the design approach focused on the conformer of docked inhibitor in BACE1, we found novel non-peptidic and small-sized BACE1 inhibitors possessing a 2,6-pyridinedicarboxylic, chelidamic or chelidonic residue at the P2 position. (c) 2008 Elsevier Ltd. All rights reserved.
• NOVEL COMPOUND HAVING BETA-SECRETASE INHIBITORY ACTIVITY
  申请人：Kiso Yoshiaki

  公开号：US20100137606A1

  公开（公告）日：2010-06-03

  A novel compound represented by the formula (1) below which has β-secretase inhibitory activity, its pharmaceutically acceptable salt or a prodrug thereof. wherein Ar is a substituted or unsubstituted 5 to 6 membered mono cyclic aromatic group; R 1 , R 2 and R 3 are hydrogen atom, substituted or unsubstituted alkyl group or the like, or R 2 and R 3 may be taken together with the adjacent nitrogen atom and carbon atom respectively to form a 3 to 6 membered ring; R 4 is C 1-6 alkyl group, C 1-6 alkyl group substituted by phenyl, phenylthio, or a hetero ring, or the like; A is represented by the formula below: wherein X and Y are oxygen atom, NH or sulfur atom, Z is hydrogen atom, hydroxy group which may be substituted, amino group, thiol group, or the like; and B is hydroxy group, substituted or unsubstituted amino group, substituted or unsubstituted aliphatic or aromatic amino group, or the like.
• US8344002B2
  申请人：——

  公开号：US8344002B2

  公开（公告）日：2013-01-01